Search Results - "Bouberhan, S."

754P Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study by O'Cearbhaill, R.E., Moore, K.N., Yeku, O., Liu, J.F., Bouberhan, S., Hamilton, E.P., Hou, J.Y., Van Nieuwenhuysen, E., Papadimitriou, K., Yoo, S-Y., Govindraj, S., Brouwer-Visser, J., Peterman, M., Schmidt, T., Barnes, B., Madia, P., Zhu, M., Uldrick, T.S., Miller, E.A., O'Malley, D.

Get full text

523MO Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis by Van Nieuwenhuysen, E., O'Malley, D., O'Cearbhaill, R.E., Moore, K.N., Hamilton, E.P., Yeku, O., Bouberhan, S., Hou, J.Y., Yoo, S-Y., Brouwer-Visser, J., Cheung, H.K., Peterman, M., Goncalves, P., Schmidt, T., Zhu, M., Lowy, I., Rowlands, T., Uldrick, T.S., Miller, E.A., Liu, J.F.

Get full text

LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer by Konstantinopoulos, P.A., Gockley, A.A., Xiong, N., Tayob, N., Krasner, C.N., Buss, M., Campos, S., Schumer, S., Wright, A.A., Liu, J.F., Shea, M., Oladapo, Y., Castro, C., Polak, M.M., Whalen, C., Bouberhan, S., Cannistra, S.A., Penson, R.T., Fleming, G., Matulonis, U.A.

Get full text

127P REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study by Winer, I.S., O'Cearbhaill, R.E., Bouberhan, S., Hays, J.L., Wenham, R.M., Roque, D.R., Yeku, O.O., Liu, J.F., Wang, B., Yoo, S-Y., Govindraj, S., Zhu, M., Brouwer-Visser, J., Peterman, M.J., Barnes, B., Lowy, I., Knorr, D., Uldrick, T.S., Miller, E.A.

Get full text

102P Interim safety analysis of a phase II trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer by Yeku, O.O., Russo, A., Bregar, A., Brower, J., Dinesh, A., Bouberhan, S., Widick, P., Jang, J., Colella, T., Filipi, J., Eisenhauer, E.L., Kournioti, C.S., Goodman, A., Spriggs, D., Lee, H., Castro, C.M.

Get full text

41P Phase I analysis of ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer by Moore, K.N., O'Malley, D., Van Nieuwenhuysen, E., Hamilton, E., O'Cearbhaill, R.E., Yeku, O., Bouberhan, S., Hou, J.Y., Peterman, M., Goncalves, P., Schmidt, T., Yoo, S-Y., Zhu, M., Lowy, I., Rowlands, T., Uldrick, T., Miller, E.A., Liu, J.

Get full text

197TiP First-in-human (FIH) phase I/II study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC) by Moore, K.N., Bouberhan, S., Hamilton, E., Liu, J., O'Cearbhaill, R.E., O'Malley, D., Papadimitriou, K., Schröder, D., Van Nieuwenhuysen, E., Yoo, S-Y., Peterman, M., Goncalves, P., Schmidt, T., Zhu, M., Lowy, I., Uldrick, T., Miller, E.A.

Get full text